Taking everything into account, Bausch Health Companies Inc. (NYSE:BHC) scores Hold on the technical side. The stock is also flashing a Sell from the Barchart TrendSpotter trading system. Traders hoping to speculate on the BHC’s short-term trajectory should know that short terms indicators for the stock averaged 40% Buy with an average daily trading volume over the past 20 days at 5305740 shares. BHC stock has overall a 0.25% Buy signal considering medium term indicators and the 50-day average daily volume remained almost 4924756 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was shares, is 67% Sell on the basis of long term indicators.
The share price is currently staying around the first support level of $22.79. Below this, the next support is placed in the zone of $22.48. Till the time, the BHC stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 57.04 on daily chart, which may remain a cause for concern. If the price breaks below $22.48 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $23.35 mark may result into a pull-back move towards $23.6 level.
Bausch Health Companies Inc. (BHC) is projected to climb by 31.18 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $58price as 12-month high target. This represents a whopping 151.19 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $29.5, which represents a return potential of 27.76 percent when compared to the closing price of the stock of $23.09 on Friday, January 18. The lowest price target for the stock is $9 — slightly more than -61.02 percent from BHC’s current share price.
Here’s a rundown of insider trading activity for sense of Bausch Health Companies Inc. (NYSE:BHC). The earliest insider trade took place on 12/14/2018. Appio Thomas gathered a total of 25.44 thousand shares of company at average share price of $22.96. The total for the purchase was set at $584.1 thousand. After this transaction, the Pres&Co-Head Bausch&Lomb/Int’l account balance stood at 154.36 thousand shares. The stock grew 0.57 percent since that insider purchase. On 10/16/2018, Ackermann Christina, EVP AND GENERAL COUNSEL, sold 19.95 thousand shares at a price per share of $24.98. This removed 498.25 thousand shares from the insider’s fortune and the stock saw a -7.57 percent retreat in value since the news became public. This transaction left 51.46 thousand shares in the EVP AND GENERAL COUNSEL account. On 09/14/2018, CHAIRMAN & CEO Papa Joseph C performed a purchase transaction worth $669.6 thousand. This purchase at $22.32 each has added 30 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded 3.45 percent increase since the transaction was reported. The insider now is left with 687.08 thousand shares remaining in the account. Herendeen Paul, who performs the EVP and CFO job, bought 10 thousand shares for $226.1 thousand. The acquisition occurred on 09/14/2018 was priced at $22.61 per share. The share price soared 2.12 percent since the reporting date. Herendeen Paul now left with a stake of 226.87 thousand BHC stock worth $5.24 million after the insider buying.
BHC shares accumulated 0.06 points or 0.26 percent on Monday to $23.09 with a light trade volume of 3.897 million shares. After opening the session at $23.08, the shares went as high as $23.3 and as low as $22.74, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $8.06 billion and now has 348.93 million shares outstanding. Bausch Health Companies Inc. (BHC) stock has gained 10.69 percent of market value in 21 trading days.
Analysts at Piper Jaffray upped their rating on shares of Bausch Health Companies Inc. (NYSE:BHC) from Neutral to Overweight in their opinion released on January 02. Morgan Stanley analysts bumped their recommendation on BHC stock from Equal-Weight to Overweight in a separate flash note to investors on November 05. Analysts at Piper Jaffray issued an upgrade from Underweight to Neutral for the stock, in a research note that dated back to September 13.
BHC stock has a trailing 3-year beta of 0.44, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$12.14 a share in the trailing twelve months. The stock’s value has surged 25.01 percent year to date (YTD) against a rise of 4.48 percent in 12 month’s time. The company’s shares still trade -18.84 percent away from its 1-year high of $28.45 and 59.9 percent up from 52-week low of $14.44. The average consensus rating on the company is 2.7, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.
Shares of Bausch Health Companies Inc. (BHC) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry BHC operates in has an average P/E of 30.48. Its P/E ratio went as low as 55.49X and as high as 55.49 over the 5-year span. Further, it is sporting a 0.96 on the Price-to-Sales ratio. Compare this with the industry average P/S of 4.12. 71.6 percent is the gross profit margin for Bausch Health Companies Inc. and operating margin sits at -34 percent. Along with this, the net profit margin is -39.1 percent.
BHC will be declaring its Q4 financial results on February 28. Analysts are forecasting revenue to suffer decline of -3.7 percent to $2.08B in the next fiscal quarter, while earnings are seen soaring by nearly -14.29 percent to $0.84 per share. History has shown that shares in Bausch Health Companies Inc. have gone up on 3 different earnings reaction days and are predicted to add 0.07 percent when the company reports upcoming earnings. In last reported earnings results, it earned $1.13 per share, better than the $0.84, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $2.14B, better than the $2.09B analysts expected. Earnings are estimated to increase by 158.6 percent this year, 0.13 percent next year and continue to increase by 7.05 percent annually for the next 5 years.